Federal Register / Vol. 74, No. 114 / Tuesday, June 16, 2009 / Notices 28507 

ESTIMATES OF ANNUAL BURDEN HOURS

Type of 

respondents Survey instrument Number of respondents 

Frequency of 

response 

Average time 

per response 

(hours) 

Annual 

burden hours 

Clinical Trials ..................................... Initial Registration ............................. 5,500 1 2.0 11,000 

Amendment ...................................... 5,500 4 1.0 22,000 

Total ........................................... ........................................................... ........................ ........................ ........................ 33,000 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies should 

address one or more of the following 

points: (1) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the function of the agency, including 

whether the information will have 

practical utility; (2) Evaluate the 

accuracy of the agency’s estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Minimize the burden 

of the collection of information on those 

who are to respond, including the use 

of appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the 

Attention: NIH Desk Officer, Office of 

Management and Budget, at 

OIRA_submission@omb.eop.gov or by 

fax to 202–395–6974. To request more 

information on the proposed project or 

to obtain a copy of the data collection 

plans and instruments, contact John 

Speakman, Associate Director for 

Clinical Trials Products and Programs, 

Center for Biomedical Informatics and 

Information Technology, National 

Cancer Institute, NIH, DHHS, 2115 E. 

Jefferson Street, Suite 6000, Rockville, 

MD 20892 or call non-toll-free number 

301–451–8786 or e-mail your request, 

including your address to: 

john.speakman@nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 15 days of the date of 

this publication. 

Dated: June 9, 2009. 

Vivian Horovitch-Kelley, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. E9–14089 Filed 6–15–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Office of Refugee Resettlement; 

Single-Source Program Expansion 

Supplement to the Lutheran Social 

Services of South Dakota (LSS–SD) 

Under the South Dakota Wilson-Fish 

Program, Award 

AGENCY: Office of Refugee Resettlement, 

ACF, HHS. 

ACTION: Notice to award a single-Source 

program expansion supplement to the 

Lutheran Social Services of South 

Dakota (LSS–SD) under the South 

Dakota Wilson-Fish Program. 

CFDA Number: 93.583. 

Legislative Authority: The Refugee Act 

of 1980 as amended, Wilson-Fish 

Amendment, 8 U.S.C. 1522(e)(7); 

section 412(e)(7)(A) of the Immigration 

and Nationality Act. 

Amount of Award: $125,000. 

Project Period: 09/30/2007–09/29/ 

2010 

Justification for the Exception to 

Competition: The Wilson-Fish program 

is an alternative to the traditional Stateadministered refugee assistance program 

for providing integrated assistance and 

services to refugees, asylees, Amerasian 

Immigrants, Cuban and Haitian 

Entrants, Trafficking Victims and Iraqi/ 

Afghani SIV’s. South Dakota is one of 12 

sites that has chosen this alternative 

approach. 

The supplemental funds will allow 

the grantee, LSS–SD, located in Sioux 

Falls, SD, to provide refugee cash 

assistance through the end of this fiscal 

year to eligible refugees (and others 

eligible for refugee benefits) under the 

South Dakota Wilson-Fish Program. 

The primary reason for the grantee’s 

supplemental request is a higher 

number of arrivals than anticipated 

when the grantee’s budget was 

submitted and approved last year. The 

Refugee Act of 1980 mandates that the 

Office of Refugee Resettlement (ORR) 

reimburse States and Wilson-Fish 

projects for the costs of cash and 

medical assistance for newly arriving 

refugees. Since 1991, ORR has 

reimbursed States and Wilson-Fish 

agencies for providing cash and medical 

assistance to eligible individuals during 

their first eight months in the United 

States. Hence, the supplement is 

consistent with the purposes of the 

Wilson-Fish Program, the Refugee Act of 

1980, and ORR policy. 

CONTACT FOR FURTHER INFORMATION: Carl 

Rubenstein, Wilson-Fish Program 

Manager, Office of Refugee 

Resettlement, Aerospace Building, 8th 

Floor West, 901 D Street, SW., 

Washington, DC 20447. Telephone: 

202–205–5933, E-mail: 

crubenstein@acf.hhs.gov. 

Dated: 06/04/2009. 

David H. Siegel, 

Acting Director, Office of Refugee 

Resettlement. 

[FR Doc. E9–14140 Filed 6–15–09; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories Which 

Meet Minimum Standards To Engage in 

Urine Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories currently 

certified to meet the standards of 

Subpart C of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908), 

on September 30, 1997 (62 FR 51118), 

and on April 13, 2004 (69 FR 19644). 

A notice listing all currently certified 

laboratories is published in the Federal 

Register during the first week of each 

month. If any laboratory’s certification 

mstockstill on PROD1PC66 with NOTICES

28508 Federal Register / Vol. 74, No. 114 / Tuesday, June 16, 2009 / Notices 

is suspended or revoked, the laboratory 

will be omitted from subsequent lists 

until such time as it is restored to full 

certification under the Mandatory 

Guidelines. 

If any laboratory has withdrawn from 

the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end, 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http:// 

www.workplace.samhsa.gov and http:// 

www.drugfreeworkplace.gov. 

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh, Division of Workplace 

Programs, SAMHSA/CSAP, Room 2– 

1042, One Choke Cherry Road, 

Rockville, Maryland 20857; 240–276– 

2600 (voice), 240–276–2610 (fax). 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were developed 

in accordance with Executive Order 

12564 and section 503 of Public Law 

100–71. Subpart C of the Mandatory 

Guidelines, ‘‘Certification of 

Laboratories Engaged in Urine Drug 

Testing for Federal Agencies,’’ sets strict 

standards that laboratories must meet in 

order to conduct drug and specimen 

validity tests on urine specimens for 

Federal agencies. To become certified, 

an applicant laboratory must undergo 

three rounds of performance testing plus 

an on-site inspection. To maintain that 

certification, a laboratory must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories which claim to be in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A laboratory 

must have its letter of certification from 

HHS/SAMHSA (formerly: HHS/NIDA) 

which attests that it has met minimum 

standards. 

In accordance with Subpart C of the 

Mandatory Guidelines dated April 13, 

2004 (69 FR 19644), the following 

laboratories meet the minimum 

standards to conduct drug and specimen 

validity tests on urine specimens: 

ACL Laboratories, 8901 W. Lincoln 

Ave., West Allis, WI 53227, 414–328– 

7840/800–877–7016 (Formerly: 

Bayshore Clinical Laboratory). 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

585–429–2264. 

Advanced Toxicology Network, 3560 

Air Center Cove, Suite 101, Memphis, 

TN 38118, 901–794–5770/888–290– 

1150. 

Aegis Analytical Laboratories, 345 Hill 

Ave., Nashville, TN 37210, 615–255– 

2400 (Formerly: Aegis Sciences 

Corporation, Aegis Analytical 

Laboratories, Inc.). 

Baptist Medical Center-Toxicology 

Laboratory, 9601 I–630, Exit 7, Little 

Rock, AR 72205–7299, 501–202–2783 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center). 

Clendo Reference Laboratory, Avenue 

Santa Cruz #58, Bayamon, Puerto Rico 

00959, 787–620–9095. 

Clinical Reference Lab, 8433 Quivira 

Road, Lenexa, KS 66215–2802, 800– 

445–6917. 

Doctors Laboratory, Inc., 2906 Julia 

Drive, Valdosta, GA 31602, 229–671– 

2281. 

DrugScan, Inc., P.O. Box 2969, 1119 

Mearns Road, Warminster, PA 18974, 

215–674–9310. 

DynaLIFE Dx*, 10150–102 St., Suite 

200, Edmonton, Alberta, Canada T5J 

5E2, 780–451–3702/800–661–9876 

(Formerly: Dynacare Kasper Medical 

Laboratories). 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609. 

Gamma-Dynacare Medical 

Laboratories*, A Division of the 

Gamma-Dynacare Laboratory 

Partnership, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630. 

Kroll Laboratory Specialists, Inc., 1111 

Newton St., Gretna, LA 70053, 504– 

361–8989/800–433–3823 (Formerly: 

Laboratory Specialists, Inc.). 

Kroll Laboratory Specialists, Inc., 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130 (Formerly: 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.). 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986 

(Formerly: Roche Biomedical 

Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group). 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339 (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center). 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.,). 

Maxxam Analytics*, 6740 Campobello 

Road, Mississauga, ON, Canada L5N 

2L8, 905–817–5700, (Formerly: 

Maxxam Analytics Inc., NOVAMANN 

(Ontario), Inc.). 

MedTox Laboratories, Inc., 402 W. 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244. 

MetroLab-Legacy Laboratory Services, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295. 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417, 612–725– 

2088. 

National Toxicology Laboratories, Inc., 

1100 California Ave., Bakersfield, CA 

93304, 661–322–4250/800–350–3515. 

One Source Toxicology Laboratory, Inc., 

1213 Genoa-Red Bluff, Pasadena, TX 

77504, 888–747–3774 (Formerly: 

University of Texas Medical Branch, 

Clinical Chemistry Division; UTMB 

Pathology-Toxicology Laboratory). 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942 (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory). 

Pathology Associates Medical 

Laboratories, 110 West Cliff Dr., 

Spokane, WA 99204, 509–755–8991/ 

800–541–7891x7. 

Phamatech, Inc., 10151 Barnes Canyon 

Road, San Diego, CA 92121, 858–643– 

5555. 

Quest Diagnostics Incorporated, 3175 

Presidential Dr., Atlanta, GA 30340, 

770–452–1590/800–729–6432 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

Quest Diagnostics Incorporated, 7600 

Tyrone Ave., Van Nuys, CA 91405, 

866–370–6699/818–989–2521 

(Formerly: SmithKline Beecham 

Clinical Laboratories). 

S.E.D. Medical Laboratories, 5601 Office 

Blvd., Albuquerque, NM 87109, 505– 

727–6300/800–999–5227. 

South Bend Medical Foundation, Inc., 

530 N. Lafayette Blvd., South Bend, 

IN 46601, 574–234–4176 x276. 

mstockstill on PROD1PC66 with NOTICES

Federal Register / Vol. 74, No. 114 / Tuesday, June 16, 2009 / Notices 28509 

Southwest Laboratories, 4625 E. Cotton 

Center Boulevard, Suite 177, Phoenix, 

AZ 85040, 602–438–8507/800–279– 

0027. 

St. Anthony Hospital Toxicology 

Laboratory, 1000 N. Lee St., 

Oklahoma City, OK 73101, 405–272– 

7052. 

Sterling Reference Laboratories, 2617 

East L Street, Tacoma, Washington 

98421, 800–442–0438. 

Toxicology & Drug Monitoring 

Laboratory, University of Missouri 

Hospital & Clinics, 301 Business Loop 

70 West, Suite 208, Columbia, MO 

65203, 573–882–1273. 

Toxicology Testing Service, Inc., 5426 

N.W. 79th Ave., Miami, FL 33166, 

305–593–2260. 

US Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235, 301–677–7085. 

The following laboratory voluntarily 

withdrew from the NLCP on May 30, 

2009: 

Diagnostic Services, Inc., dba DSI, 

12700 Westlinks Drive, Fort Myers, 

FL 33913, 239–561–8200/800–735– 

5416. 

*The Standards Council of Canada 

(SCC) voted to end its Laboratory 

Accreditation Program for Substance 

Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that 

program were accredited to conduct 

forensic urine drug testing as required 

by U.S. Department of Transportation 

(DOT) regulations. As of that date, the 

certification of those accredited 

Canadian laboratories will continue 

under DOT authority. The responsibility 

for conducting quarterly performance 

testing plus periodic on-site inspections 

of those LAPSA-accredited laboratories 

was transferred to the U.S. HHS, with 

the HHS’ NLCP contractor continuing to 

have an active role in the performance 

testing and laboratory inspection 

processes. Other Canadian laboratories 

wishing to be considered for the NLCP 

may apply directly to the NLCP 

contractor just as U.S. laboratories do. 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (Federal 

Register, July 16, 1996) as meeting the 

minimum standards of the Mandatory 

Guidelines published in the Federal 

Register on April 13, 2004 (69 FR 

19644). After receiving DOT 

certification, the laboratory will be 

included in the monthly list of HHScertified laboratories and participate in 

the NLCP certification maintenance 

program. 

Dated: June 8, 2009. 

Elaine Parry, 

Director, Office of Program Services, 

SAMHSA. 

[FR Doc. E9–14084 Filed 6–15–09; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket Numbers NIOSH–083 Supplied Air 

Respirators, NIOSH 148 Air Fed Ensembles, 

NIOSH–168 Total Inward Leakage (for 

respirators other than filtering facepieces 

and halfmasks)] 

Notice of Public Meeting To Discuss 

NIOSH’s Respirator Standards 

Development Efforts 

Authority: 29 U.S.C. 651 et seq. 

AGENCY: The National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice of a public meeting. 

SUMMARY: The National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and prevention (CDC), will 

conduct a public meeting to discuss 

current respirator standards 

development projects for Supplied Air 

Respirators (SAR); Air Fed Ensembles; 

and Total Inward Leakage (TIL) for 

respirators other than filtering 

facepieces and halfmasks. There will be 

an opportunity for discussion following 

NIOSH’s presentations and an 

accompanying poster session. 

Public Meeting Time and Date: 8:30 

a.m. to 5 p.m., September 17, 2009. Onsite registration will be held beginning 

at 7:45 a.m. 

Place: Hyatt Regency Pittsburgh 

International Airport, 1111 Airport 

Boulevard, Pittsburgh, PA 15231. 

Interested parties should make hotel 

reservations directly with the Hyatt 

Regency Pittsburgh International 

Airport by calling (800) 233–1234, 

before the cut-off date of September 2, 

2009. You must reference the NIOSH 

room block to receive the special group 

rate of $114.00 per night that has been 

negotiated for meeting guests. 

Status: The meeting will be open to 

the public, limited only by the space 

available. The meeting room 

accommodates approximately 200 

people. 

Instructions: Requests to make 

presentations at the public meeting 

should be mailed to the NIOSH Docket 

Office, Robert A. Taft Laboratories, MS– 

C34, 4676 Columbia Parkway, 

Cincinnati, OH 45226. Requests may 

also be submitted by telephone (513) 

533–8611, facsimile (513) 533–8285, or 

e-mailed to niocindocket@cdc.gov. All 

requests to present should contain the 

name, address, telephone number, and 

relevant business affiliations of the 

presenter, topic of the presentation, and 

the approximate time requested for the 

presentation. Oral presentations should 

be limited to 15 minutes. 

After reviewing the requests for 

presentations, NIOSH will notify the 

presenter that his/her presentation is 

scheduled. If a participant is not present 

when their presentation is scheduled to 

begin, the remaining participants will be 

heard in order. At the conclusion of the 

meeting, an attempt will be made to 

allow presentations by any scheduled 

participants who missed their assigned 

times. Attendees who wish to speak but 

did not submit a request for the 

opportunity to make a presentation may 

be given this opportunity at the 

conclusion of the meeting, at the 

discretion of the presiding officer. 

This meeting will also be using 

Audio/LiveMeeting Conferencing, 

remote access capabilities where 

interested parties may listen in and 

review the presentations over the 

internet simultaneously. Parties 

remotely accessing the meeting will 

have the opportunity to ask questions 

during the open comment period. To 

register to use this capability, please 

contact the National Personal Protective 

Technology Laboratory(NPPTL), Policy 

and Standards Development Branch, 

Post Office Box 18070, 626 Cochrans 

Mill Road, Pittsburgh, PA 15236, 

telephone (412) 386–5200, facsimile 

(412) 386–4089. This option will be 

available to participants on a first come, 

first serve basis and is limited to the 

first 50 participants. 

Background: NIOSH, National 

Personal Protective Technology 

Laboratory (NPPTL), will present 

information to attendees concerning the 

development of the concepts being 

considered regarding updated 

performance criteria for the various 

classes of respirators in 42 Code of 

Federal Regulations, Part 84. 

Participants will be given an 

opportunity to ask questions and to 

present individual comments that they 

may wish to have considered. 

FOR FURTHER INFORMATION CONTACT: 

Jonathan Szalajda, NPPTL, Policy and 

Standards Development Branch, Post 

Office Box 18070, 626 Cochrans Mill 

Road, Pittsburgh, PA 15236, telephone 

mstockstill on PROD1PC66 with NOTICES